A share price of Aclaris Therapeutics Inc [ACRS] is currently trading at $1.29, down -4.44%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ACRS shares have gain 9.32% over the last week, with a monthly amount glided 17.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on December 23, 2024, and kept the price target unchanged to $20. On November 20, 2024, upgrade upgraded it’s rating to Overweight. Leerink Partners upgraded its rating to a Outperform and increased its price target to $7 on November 19, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $7 on November 19, 2024. BTIG Research upgraded its rating to Buy for this stock on November 19, 2024, but kept the price target unchanged to $8. In a note dated November 18, 2024, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $3 to $13.
Aclaris Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.95 and $5.17. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $1.29 at the most recent close of the market. An investor can expect a potential return of 733.33% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
Trailing Twelve Months sales for Aclaris Therapeutics Inc [NASDAQ:ACRS] were 17.78M which represents -39.32% decline. Gross Profit Margin for this corporation currently stands at 0.21% with Operating Profit Margin at -7.92%, Pretax Profit Margin comes in at -7.32%, and Net Profit Margin reading is -7.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.92 and Total Capital is -0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aclaris Therapeutics Inc [NASDAQ:ACRS] is 5.06. As well, the Quick Ratio is 5.06, while the Cash Ratio is 1.41. Considering the valuation of this stock, the price to sales ratio is 7.86, the price to book ratio is 0.97.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased. 10% Owner, Leonard Braden Michael completed a deal on Aug 05 ’24 to buy 0.21 million shares. Meanwhile, 10% Owner Leonard Braden Michael bought 0.17 million shares on Aug 02 ’24.
